日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

An acute intervention experimental study on the effects of green and blue environment exposure combined with tai chi exercise on the emotional health of elderly males

一项关于绿色和蓝色环境暴露结合太极拳锻炼对老年男性情绪健康影响的急性干预实验研究

Zhang, Maolin; Zhang, Yin; Zhang, Zhiyao; Sun, Hongmei

34. The effect of virtual reality technology in the treatment of mild mental disorders

34. 虚拟现实技术在治疗轻度精神障碍中的作用

Xiang, Yuxin; Yao, Yilei; Jiang, Lin; Sun, Dan; Jiang, Jun; Liu, Zhisheng; Wang, Yaping; Liang, Pengju; Deng, Haiyang; Deng, Yasong; Yi, Bu Ren Bai; Wang, Furui; Li, Jingwen; Lin, Yitong; Su, Xiaoyi; Zuo, Zhikai; Li, Shuang; Yasin, M Al Imran; Wei, Chaoying; Ou, Wenhui; Han, Lintong; Wang, Pengjia; Li, Jing; Zhu, Yue; Du, Xinrui; Feng, Yingge; Deng, Haiyang; Deng, Yasong; Qian, Jiang; Jiang, Qiong; Gen, E Er Dun Ba; Zhao, Hui; Li, Xueyan; Chen, Pengyu; Jiang, Yong; Qiu, Jinping; Han, Xichun; Zou, Han; Yu, Miao; Chen, Yanrong; Chen, Yuanfeng; Wei, Wei; Chen, Xu; Cui, Mengdi; Zhang, Haojian; Xu, Xiaohan; Zhang, Kaiyue; Deng, Bowen; Wei, Zhong; Zhang, Guofang; Zhang, Meiping; Zhang, Genlei; Li, Lingheng; Chen, Xu; Huang, He; Xu, Mingge; Li, Zhiqiang; Zheng, Shuqing; Liu, Xiaoxue; Wang, Dong; Qi, Zailin; Xie, Weidong; Li, Yuepeng; Wang, Fenglin; Xu, Zhaoxi; Wang, Aijun; Tang, Yun; Wang, Zhiying; Yang, Tingting; Chen, Jinwen; Hong, Bo; Liang, Jing; Duo, Luoken; Ma, Liya; Li, Yunqi; Li, Guangmao; Deng, Haiyang; Deng, Yasong; Sun, Nannan; Wu, Xiaofei; Qiu, Tao; Wu, Huilin; Gao, Fei; Fei, Laichuang; Jiang, Lijun; Zhang, Faping; Xie, Guangjie; Sun, Zengting; Guan, Jingqi; Ji, Tao; Yue, Geni; Li, Qianqian; Ai, Hongjuan; Fan, Xinyuan; Wang, Shaozheng; Guo, Shujun; Tang, Huankun; Nie, Huiying; Zheng, Liwei; Wu, Xiaofei; Zhao, Yun; Jia, Huanhuan; Li, Dehe; Huang, Xiaojing; Han, Qiong; Deng, Haiyang; Deng, Yasong; Zhang, Yue; Qin, Chunlin; Zhang, Yefei; Zhou, Xiaohui; Zheng, Bin; Yu, Miao; Shi, Manman; Qu, Dan; Liu, Lingling; Tan, Zhi; Liu, Tong; Shan, Shuzhi; Yang, Zhou; Zhu, Yue; Wei, Zhong; Zhang, Genlei; Ma, Yiwen; Lu, Yao; Yuan, Ziyu; Yang, Ru; She, Fang; Tian, Dongge; Liu, Lingling; Gao, Chenglin; Li, Qianqian; Ai, Hongjuan; Zhang, Chunbo; Song, Ximeng; Lyu, Fulian; Chen, Jie; Bing, Qilun; Wan, Huiying; Deng, Yanlin; Deng, Yuanliang; Liu, Yongshi; Li, Jiangli; Wang, Xiaofei; Zhu, Yue; Wang, Xiaoyan; Liang, Zhimin; Xu, Shaocong; Liu, Wenwen; Zhao, Yun; Huang, Xiaojing; Jia, Huanhuan; Li, Dehe; Shu, Hui; Lin, Wei; Ge, Ming; Liu, Xiafei; Rong, Shuai; Li, Kaiwei; Ma, Zihan; Wang, Shujuan; Leng, Dejun; Liu, Xuelei; Zhou, Yiyu; Wang, Ruimei; Liu, Qingming; Bi, Qingbo; Zhang, Deyang; Tang, Yuwei; Cao, Yanqin; Rao, Fan; Guo, Yixiong; Li, Baochang; Yan, Kunying; Mo, Shengyang; Jiang, Ciling; Yang, Qin; Hu, Fang; Qi, Fuli; Zhao, Xin; Ouyang, Yun; Liu, Qun; Zheng, Juan; Xu, Ming; Guo, Jingzhi; Tong, Kana; Lu, Chunyan; Li, Yuanzhe; Zhang, Jian; Sun, Hongmei; Liu, Min; Su, Xiaoyan; Bai, Yalu; Deng, Haiyang; Deng, Yasong; Sun, Xin; Li, Hao; Ma, Wenjing; Li, Juan; Li, Guangmao; Wang, Ping; Hu, Zhifeng; Jiang, Bin; Song, Dan; Li, Yiyuan; Jiang, Yaqiong; Song, Donghui; Zhang, Yefei; Zhao, Yong; Bo, Guoxin; Gao, Pan; Bu, Lingfang; Chen, Liu; Li, Ran; Liu, Xudong; Yang, Chao; An, Le; Wang, Yajian; Wang, Junqiao; Zhang, Fangfang; Li, Lingjuan; Lu, Zhaona; Xu, Xin; Jiang, Haoran; Li, Jiangnan; Li, Jia; Yang, Bing; Li, Yiyuan

Finotonlimab (PD-1 inhibitor) plus bevacizumab (bevacizumab biosimilar) as first-tier therapy for late-stage hepatocellular carcinoma: a randomized phase 2/3 trial

Finotonlimab(PD-1抑制剂)联合贝伐单抗(贝伐单抗生物类似药)作为晚期肝细胞癌的一线治疗方案:一项随机2/3期试验

Zhao, Chuanhua; Zhang, Yanqiao; Wang, Gang; Zheng, Jinfang; Chen, Weiqing; Lu, Zheng; Zhuang, Li; Gu, Shanzhi; Han, Lei; Zheng, Zhendong; Yu, Zujiang; Yang, Yongsheng; Sun, Hongmei; Wei, Xiaoyong; Cheng, Ying; Lin, Hailan; Zhu, Bo; Wu, Guicheng; Lei, Kaijian; Wang, Wei; Wang, Yuwen; Chen, Kehe; Xu, Ximing; Zheng, Cuiping; Bi, Yanzhi; Ding, Sijuan; Zhang, Jingdong; Li, Wei; Liu, Hailong; Wang, Jun; Liu, Xianling; Du, Yangfeng; Cai, Lianming; Wang, Jingran; Luo, Zhanxiong; Xing, Baocai; Shen, Jie; Yang, Lin; Wu, Jianbing; Jiang, Ou; Peng, Zhigang; Liu, Xiuli; Cao, Bangwei; Shen, Liangfang; Xu, Aibing; Li, Aimin; Chen, Shaojun; Fu, Ting; Chen, Jian; Jin, Chuan; Zhang, Lei; Lv, Jun; Zhang, Chengwu; Zhang, Xiaoman; Wang, Yu; Su, Huo; Zhou, Qiang; Gai, Wenlin; Xie, Liangzhi; Xu, Jianming

A multicenter, randomized, double-blind, placebo-controlled phase 3 study of Socazolimab or placebo combined with carboplatin and etoposide in the first-line treatment of extensive-stage small cell lung cancer

一项多中心、随机、双盲、安慰剂对照的3期临床研究,旨在评估索卡唑利单抗或安慰剂联合卡铂和依托泊苷一线治疗广泛期小细胞肺癌的疗效。

Chen, Zhiwei; Chen, Jianhua; Huang, Dingzhi; Zhang, Wei; Wu, Lin; Yi, Tienan; Wang, Qiming; Han, Liang; Tan, Liping; Li, Yinyin; Zhang, Zhihong; Li, Na; Li, Jie; Zhang, Tongmei; Hu, Ying; Sun, Hongmei; Wu, Youhua; He, Zhiyong; Yang, Runxiang; Cheng, Peng; Li, Xingya; Shi, Jianhua; Yu, Guohua; Ma, Daiyuan; Li, Benjamin Xiaoyi; Dai, Xiangrong; Wong, Michael; Li, Yujie; Yu, Xiaohui; Lu, Shun

Novel CDK2/4/6 inhibitor culmerciclib (TQB3616) plus fulvestrant in previously treated, HR-positive, HER2-negative advanced breast cancer: a randomized, double-blind, phase 3 trial

新型 CDK2/4/6 抑制剂 culmerciclib (TQB3616) 联合氟维司群治疗既往接受过治疗的 HR 阳性、HER2 阴性晚期乳腺癌:一项随机、双盲、3 期试验

Yin, Yongmei; Zhang, Qingyuan; Sun, Tao; Hao, Chunfang; Wang, Zhihong; Yang, Jin; Wang, Yongsheng; Shi, Yanxia; Sun, Jing; Ouyang, Quchang; Su, Haichuan; Wu, Jinsheng; Gan, Lu; Han, Meng; Gao, Liming; Wang, Xiaojia; Zhao, Bing; Li, Hui; Zhao, Jiuda; Yang, Hongwei; Ning, Fangling; Tian, Fuguo; Zhang, Juliang; Sun, Hongmei; Niu, Zhaofeng; Zong, Hong; Zang, Aimin; Wang, Xinshuai; Qian, Xinyu; Wu, Shikai; Nie, Jianyun; He, Lijia; Cheng, Ying; Hao, Yanrong; Zhai, Yi; Li, Huiping; Wang, Jingfen; Wei, Shihong; Li, Man; Liu, Yunjiang; Guo, Hongqiang; Hu, Qun; Liu, Lina; Han, Xinghua; Luo, Ruizhen; Ni, Mingli; Tang, Xianjun; Zhai, Zhenhua; Ding, Meiqian; Wang, Haibo; Shen, Peng; Wang, Xian; Liu, Lian; Chen, Wenyan; Liu, Gang; Cai, Zhengwen; Jiang, Zefei

Efficacy and safety of KN026 and docetaxel for HER2-positive breast cancer: a phase II clinical trial

KN026联合多西他赛治疗HER2阳性乳腺癌的疗效和安全性:一项II期临床试验

Ma, Jianli; Wang, Jingxuan; Xu, Ting; Ouyang, Quchang; Wang, Xiaojia; Wang, Jingfen; Gan, Lu; Ouyang, Zhong; Lin, Daren; Sun, Tao; Shan, Changping; Yao, Herui; Zhang, Baochun; Li, Zhengguang; Zhuang, Zhixiang; Lu, Ying; Yang, Hongwei; Huang, Jian; Yang, Xingwang; Sun, Hongmei; Zhang, Qingyuan

Design of precision therapeutics for a CKD risk allele by targeting Shroom3-Rock interaction

通过靶向Shroom3-Rock相互作用设计针对CKD风险等位基因的精准疗法。

Anand Reghuvaran #,Ashwani Kumar #,Qisheng Lin,Nallakandi Rajeevan,Khadija Banu,Zeguo Sun,Hongmei Shi,Gabriel Barsotti,E M Tanvir,John Pell,Sudhir Perincheri,Chengguo Wei,Bhavya Bharathan,Marina Planoutene,Anne Eichmann,Valeria Mas,Weijia Zhang,Lloyd G Cantley,Leyuan Xu,Bhaskar Das,John Cijiang He,Madhav C Menon

Global, regional and national burden of rheumatoid arthritis from 1990 to 2021, with projections of incidence to 2050: a systematic and comprehensive analysis of the Global Burden of Disease study 2021

1990年至2021年全球、区域和国家类风湿性关节炎负担,以及至2050年的发病率预测:2021年全球疾病负担研究的系统性和综合性分析

Ma, Yingnan; Chen, Haiyan; Lv, Wenhua; Wei, Siyu; Zou, Yuping; Li, Ruilin; Wang, Jiacheng; She, Wei; Yuan, Linna; Tao, Junxian; Guo, Xuying; Bi, Shuo; Tian, Hongsheng; Ma, Ye; Sun, Hongmei; Sun, Chen; Xu, Jing; Dong, Yu; Kang, Jingxuan; Lv, Hongchao; Zhang, Mingming; Jiang, Yongshuai

Global, regional, national burden of asthma from 1990 to 2021, with projections of incidence to 2050: a systematic analysis of the global burden of disease study 2021

1990年至2021年全球、区域和国家哮喘负担,以及至2050年的发病率预测:2021年全球疾病负担研究的系统分析

Yuan, Linna; Tao, Junxian; Wang, Jiacheng; She, Wei; Zou, Yuping; Li, Ruilin; Ma, Yingnan; Sun, Chen; Bi, Shuo; Wei, Siyu; Chen, Haiyan; Guo, Xuying; Tian, Hongsheng; Xu, Jing; Dong, Yu; Ma, Ye; Sun, Hongmei; Lv, Wenhua; Shang, Zhenwei; Jiang, Yongshuai; Lv, Hongchao; Zhang, Mingming

Antlers on does: An unexpected role of macrophages in deer biology.

母鹿的鹿角:巨噬细胞在鹿生物学中发挥的意想不到的作用

Wang Datao, Ba Hengxing, Li Xunsheng, Landete-Castillejos Tomas, Shi Wanwan, Wang Zhen, Ren Jing, Sun Hongmei, Chonco Louis, Ma Chao, Zhang Guokun, Melino Gerry, Shi Yufang, Li Chunyi